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Altered oligodendrocyte structure and function is implicated in major psychiatric illnesses, including low cell number and
reduced oligodendrocyte-speciﬁc gene expression in major depressive disorder (MDD). These features are also observed in the
unpredictable chronic mild stress (UCMS) rodent model of the illness, suggesting that they are consequential to environmental
precipitants; however, whether oligodendrocyte changes contribute causally to low emotionality is unknown. Focusing on
20-30-cyclic nucleotide 30-phosphodiesterase (Cnp1), a crucial component of axoglial communication dysregulated in the
amygdala of MDD subjects and UCMS-exposed mice, we show that altered oligodendrocyte integrity can have an unexpected
functional role in affect regulation. Mice lacking Cnp1 (knockout, KO) displayed decreased anxiety- and depressive-like
symptoms (i.e., low emotionality) compared with wild-type animals, a phenotypic difference that increased with age
(3–9 months). This phenotype was accompanied by increased motor activity, but was evident before neurodegenerative-
associatedmotor coordination deﬁcits(p9–12months). Notably, Cnp1
KOmicewere lessvulnerabletodeveloping adepressive-
like syndrome after either UCMS or chronic corticosterone exposure. Cnp1
KO mice also displayed reduced fear expression
during extinction, despite normal amygdala c-Fos induction after acute stress, together implicating dysfunction of an amygdala-
related neural network, and consistent with proposed mechanisms for stress resiliency. However, the Cnp1
KO behavioral
phenotype was also accompanied by massive upregulation of oligodendrocyte- and immune-related genes in the basolateral
amygdala, suggesting an attempt at functional compensation. Together, we demonstrate that the lack of oligodendrocyte-
speciﬁc Cnp1 leads to resilient emotionality. However, combined with substantial molecular changes and late-onset
neurodegeneration, these results suggest the low Cnp1 seen in MDD may cause unsustainable and maladaptive molecular
compensations contributing to the disease pathophysiology.
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Introduction
Disruptions in neuronal signaling long have been the focus of
research on major depressive disorder (MDD). More recently,
however, glial disruptions have been postulated to contribute
tothepathophysiologyofMDD,
1–3andtherolesofspecialized
glial subtypes are now being investigated. Although alter-
ations in microglia
4–6 and astrocyte-related components
7–10
are observed in MDD, oligodendrocyte alterations in MDD are
becomingaprimaryfocusofresearch.
2Oligodendrocytes,the
main myelin-forming cells of the central nervous system,
provide both structural and trophic support for neurons, and
facilitate axonal conduction. In the amygdala and prefrontal
cortexofMDD subjects,previously reported decreasesin glial
cell number were attributed to reduced oligodendrocyte
number,
11,12 consistent with patterns of downregulation of
oligodendrocyte-related transcripts in amygdala
13 and nearby
temporal cortex.
14 Changes in NG2 cells, a cell type sharing a
common lineage with oligodendrocytes,
15,16 have also been
associated with depression-related characteristics in rodents.
For instance, both chronic corticosterone exposure and
chronic stress in rodents decreased cortical and limbic
oligodendrocyte
17 and NG2 cell proliferation.
18,19 Rats given
electroconvulsive seizure therapy, an antidepressant treat-
ment for otherwise non-responsive MDD subjects, showed
increased proliferation of NG2 cells in the amygdala and
hippocampus.
18,20,21 Thus, evidence suggests that oligoden-
drocytes, a crucial element for maintaining optimal neuronal
function, may be vulnerable to stress-related insults and may
contribute to the pathophysiology of MDD.
We previously identiﬁed a set of dysregulated gene
transcripts in the amygdala of male subjects with familial
MDD, including robust downregulations of multiple oligoden-
drocyte-related genes.
13 This pattern was also observed in
mice following unpredictable chronic mild stress (UCMS)
22
and appeared restricted to the amygdala (not anterior
cingulate cortex or dentate gyrus). 20-30-Cyclic nucleotide
30-phosphodiesterase (Cnp1) was one of several oligoden-
drocyte-speciﬁc genes signiﬁcantly downregulated across
species. In addition, Cnp1 was previously implicated in
MDD
14,23 and schizophrenia,
24–26 supporting the hypothesis
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www.nature.com/tpthat altered Cnp1 function may participate in the pathophysi-
ology of psychiatric disorders. Although Cnp1 is expressed at
low levels in the periphery, it is expressed at higher levels
in NG2 cells and it comprises B4% of myelin-associated
proteins in mature oligodendrocytes.
27 Cnp1 is localized to
non-compact myelin in the inner mesaxon and paranodal
loops,
28theprinciplesitesofcontactwiththeaxon.Cnp1binds
microtubulesandregulatesmRNAexpressionandtransportat
the paranode,
29 although its exact role in axoglial commu-
nication is not known. The lack of Cnp1 protein in mice results
in disorganization of nodal sodium channels and paranodal
adhesion proteins (e.g., Caspr and Nav).
30,31 Adult Cnp1
KO
mice do not initially show an overt behavioral phenotype, but
develop progressive axonal degeneration and motor deﬁcits
after 6 months of age, leading to premature death.
30,31
Healthy oligodendrocytes are necessary to maintain opti-
mal axon function;
32 however, it remains to be determined
whether oligodendrocyte-speciﬁc alterations are causal to
MDD, as opposed to compensatory or neutral side effects in
psychiatric disorders. Here, we investigated the effect of a
lack of Cnp1 on emotionality (i.e. anxiety and depressive-like
behaviors) in mice, under baseline conditions (trait) and after
chronic stress or corticosterone exposure, two validated
paradigms for inducing high-emotionality states. To summar-
izethenumberofbehavioraltests thatwere performed,and to
obtain comprehensive and integrated measures in each
group, emotionality- and locomotion-related data were nor-
malized using a Z-score methodology previously described.
33
As the amygdala is a central region in affect regulation and as
our initial ﬁndings showed low Cnp1 in the amygdala of MDD
patients,
34 we also assessed amygdala function in Cnp1
KO
mice using fear conditioning (FC), c-Fos induction and gene
expression proﬁling. The experiments show that lack of Cnp1
results in low emotionality under baseline and induced states,
along with reduced corticolimbic fear expression, a suggested
mechanism for stress resilience.
Materials and methods
Animals. Cnp1
KO mice were obtained from KA Nave and
C. Lappe-Siefke (Max Planck Institute, Go ¨ttingen, Germany).
Adult male and female Cnp1
KO and wild-type (WT) littermate
mice (C57BL/6 background)
31 were obtained from hetero-
zygous crossings and microchipped for identiﬁcation. Five
cohorts were used: Baseline Cohort (N¼11–17 per group; 6
and 9 months baseline), UCMS Cohort (N¼8–12 per group, 6
months of age), CORT Cohort (N¼10–14 per group; 3-month
baseline and CORT exposure), FC Cohort (N¼16–19 per
group, 3 and 6 months of age) and cFos Cohort (N¼6p e r
group, 6 months of age). Mice were maintained under stan-
dard conditions (group housed, 12/12-hour light/dark cycle,
22±11C, food and water ad libitum). All testing was con-
ducted in compliance with the National Institutes of Health
laboratory animal care guidelines and with protocols approved
by the Institutional Animal Care and Use Committee.
Behavioral measures. Major depression is deﬁned as a
syndrome (i.e., collection of symptoms) including low mood or
anhedonia, accompanied by cognitive (e.g., attention,
concentration) and physiological symptoms (e.g., weight,
locomotor and sleep pattern changes), and frequently
comorbid with signiﬁcant anxiety symptoms. Thus, the
emotionality component is best characterized in mice by a
comprehensive panel of behavioral tests for anxiety-like and
depressive-like emotionality, and for antidepressant-like
behavior. Hence, Baseline, UCMS and CORT Cohorts were
tested in the elevated plus maze (EPM), open ﬁeld (OF),
novelty suppressed feeding (NSF), forced swim test (FST)
and rotarod as described,
35 and in the following order: EPM,
OF, NSF, FST, rotarod, separated by a minimum of 1–2 days.
Detailed methods are provided in the Supplementary Material.
Behavioral Z-scoring. To address behavioral variability
and obtain comprehensive and integrated measures in
each group, emotionality- and locomotion-related data
were normalized using a Z-score methodology previously
described.
33 Brieﬂy, for each behavioral measure, Z-scores
for individual animals were calculated using the formula
below, which indicates how many s.d.’s (s) an observation
(X) is above or below the mean of a control group (m).
z ¼
X   m
s
Z-scores for behavioral measures were ﬁrst averaged within
test, and then across test to ensure equal weighting of the
four tests comprising the ﬁnal Z-score (Figure 1b). Separate
Z-scores were calculated for the Baseline, UCMS and CORT
Cohorts using the means and s.d.’s of the respective control
groups (i.e., ‘WT’ for Baseline or ‘WT control’ for UCMS and
CORT). Locomotion Z-scores were similarly obtained from
EPM (total crosses) and OF (total distance traveled) data.
Estrous phase. Female mice in the UCMS and 3-month
Baseline Cohorts were assessed for estrous phase on the
day of behavioral testing after the EPM, OF and NSF tests
to control for potential effects of hormonal ﬂuctuations on
behavior. Estrus, metestrus, diestrus and proestrus were
determined via vaginal cytology
36 as previously described.
33
Unpredictable chronic mild stress. Single-housed mice
were subjected to 4 weeks of a randomized schedule of 1–2
mild stressors per day, 7 days per week. Detailed methods
are in the supplements and full table of stressors in
Supplementary Table 1.
Chronic corticosterone treatment. As described previously,
33
mice were given corticosterone (35mgml
 1; Sigma-C2505,
St Louis, MO, USA) dissolved in 20% cyclodextrin (Sigma
H107) as their only water supply for 4 weeks. Owing to the
reduced cohort size, behavior of all mice was tested both before
(3-month baseline) and following CORT exposure.
Fear conditioning. The protocol was performed over 3
days using a computer-controlled system (Coulbourn
Instruments, Allentown, PA, USA) (Figure 3a). On day 1,
mice were trained to associate a conditioned stimulus (CS;
80db, 2kHz, 15s tone) to an unconditioned stimulus (US);
0.5mA, 0.5s footshock) in context A (shock ﬂoor, silver/
aluminum walls, 70% ethanol cleanser). On day 2, mice
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ﬂoor, black walls, Windex cleanser). On day 3, mice were
placed back in context B (extinction recall) followed by
context A (fear renewal) 1h later; and freezing was recorded
during ﬁve CS exposures in each context. On each day,
a 2-min acclimation period preceded and followed testing.
Trials were presented with a variable inter-trial interval (25–
35s) and percent freezing was measured during the 15-s CS.
Immunohistochemistry. Stress-induced c-Fos immuno-
reactivity was performed as described.
37 Brains were
collected by perfusion at 120min following a 15-min
restraint stress. Sections (40mm, six per mouse) were
incubated with c-Fos antibody (polyclonal rabbit anti-c-Fos;
1:5000 dilution; Calbiochem, San Diego, CA, USA), followed
by secondary biotinylated goat-anti-rabbit IgG (1:500 dilution;
Vector Laboratories, Burlingame, CA, USA), and visualized
with diaminobenzidine solution (DAB Peroxidase Substrate
Kit; Vector Laboratories). Total numbers of c-Fos-positive
cells were counted in the basolateral amygdala (BLA).
Gene array. Brains from the UCMS Cohort (N¼11–13 mice
per group) were selected, based on emotionality Z-scores
that were closest to the means of their group. Following
dissection, brains were immediately ﬂash frozen on dry ice.
As the other hemisphere was allotted for other experi-
ments, the left BLA was dissected directly on the cryostat
using a 0.5-mm micropunch, tissue samples were frozen
at  801C until extraction and total RNA was extracted
using an RNeasy Mini Kit (Qiagen, Germantown, MD, USA).
Figure 1 Cnp1
KO baseline behavior at 3, 6 and 9 months of age. (a) Latency to fall on the rotarod. Cnp1
KO mice show signiﬁcant motor coordination deﬁcits at 9 months.
(b)ExampleofindividualbehavioralmeasurescombinedintheemotionalityZ-scores(6-monthtime-point).SeealsoMaterialsandmethods,andGuillouxetal.
33forZ-scoring
methodology. Cnp1
KO mice showed signiﬁcant changes in elevated plus maze (EPM) and forced swim test (FST), and nonsigniﬁcant changes in novelty suppressed feeding
(NSF) and open ﬁeld (OF). In NSF, no differences in weight loss or post-test food consumption were noted (data not shown). EPM, OF, NSF and FST measures were
normalized using WT means and s.d.’s, and averaged per group.
33 Breakdown of Z-scores for other age groups are presented in Supplementary Figures 1–3. (c) High
emotionalityZ-scores indicate elevatedanxiety-relatedand depressive-like behaviors. (d) Similarly derived locomotion Z-scores indicate elevated locomotor activity. Z-scores
are normalized to the 3-month WT group for both emotionality and locomotion. Red asterisks represent within-genotype age comparisons. Black asterisks represent across
genotype comparisons. Data represent mean±s.e.m. (N¼9–18 per group). *Po0.05, **Po0.01, ***Po0.001.
The role of Cnp1 in mood regulation
NM Edgar et al
3
Translational PsychiatryConcentration and purity were tested using a Bioanalyzer and
Nanodrop Spectrophotometer (260/280X1.8). One half of
each RNA sample (B150ng) was processed on Illumina
Mouse WG-6v2 Expression BeadChips (San Diego, CA,
USA) at the Keck Microarray facility (Yale University, New
Haven, CT, USA) and expression levels were determined
using the Illumina BeadArray Reader. The other half was
used for independent veriﬁcation by real-time quantitative
PCR. Two internal controls veriﬁed the validity of the arrays
(see Results): (1) Cnp1 is downregulated/absent in Cnp1
KO
and (2) Cnp1 is downregulated in WT mice following UCMS.
22
Real-time quantitative PCR. Total RNA was converted into
cDNA using the qScript cDNA synthesis kit (Quanta
Biosciences, Gaithersburg, MD, USA). As previously
described, real-time quantitative polymerase chain reaction
reactions were assessed by SYBR green ﬂuorescence signal
(Invitrogen, Carlsbad, CA, USA) using the Opticon Monitor
DNA Engine (Bio-Rad, Berkeley, CA, USA).
13 Brieﬂy,
samples were run in quadruplicates and DCt values were
determined by comparison with the geometric mean of three
reference genes (housekeeping genes: actin, GAPDH and
cyclophilin). Signal intensities (SI¼100 2
 DC(t)) were used
for comparison with microarray expression values.
Statistical analysis. There were no signiﬁcant effects of
sex or estrous phase in all examined cohorts, hence, male
and female groups were combined, where appropriate.
Genotype differences in Baseline and CORT Cohorts were
assessed using repeated measures analysis of variance
(ANOVA) for age and treatment, respectively. Genotype
comparisons with the 3-month Baseline group were made
using one-way ANOVA. The UCMS Z-scores were assessed
using a two-way ANOVA for genotype and treatment.
Weekly measures in UCMS (fur rating, body weight and
corticosterone levels) were assessed using two-way
repeated measures ANOVA for week, with genotype and
treatment as cofactors. Genotype differences in the FC
Cohort were assessed using repeated measures analysis of
covariance with age as a covariate for days 1 (conditioning)
and 2 (extinction) and one-way analysis of covariance for day
3 (recall and renewal). Genotype differences in the c-Fos
Cohort were determined using two-way ANOVA for genotype
and stress. Gene expression changes across genotype were
assessed in four subgroups: WT-Control, WT-UCMS,
KO-Control and KO-UCMS, using ANOVA followed by two-
group post hoc tests for gene selection (Supplementary
Table 2). Selection criteria were set at Po0.01 and effect
size greater than 30%. Genotype differences in real-time
quantitative PCR were assessed with one-way ANOVA.
Results
Cnp1
KO mice display low baseline/trait emotionality and
high locomotor activity. Consistent with prior reports,
Cnp1
KO mice showed normal motor coordination in the
rotarod test at 3 and 6 months of age, and showed deﬁcits in
mice aged 9 months (Figure 1a). Mice were grossly impaired
at 12 months of age and could not perform the rotarod test
(data not shown). Therefore, we tested the impact of reduced
Cnp1 on emotionality in male and female mice at 3, 6 and 9
months of age (i.e., before and during mild neurode-
generative-related stages), using four behavioral paradigms
(EPM, OF, NSF and FST). To extract stable patterns
underlying behavioral variability and summarize results
across tests, emotionality-related measures were normalized
to the 3-month WT group, and averaged per mouse across
tests to obtain integrated ‘emotionality Z-scores’
33 (See
Materials and methods, and example of 6-month time-point
in Figure 1b). Cnp1
KO mice were comparable to WT mice at 3
months of age and displayed progressively decreasing
emotionality Z-scores at 6 and 9 months of age (Figure 1c
and Supplementary Figures 1–3). It is unlikely that changes
were due to repeated testing (at 6 and 9 months) as a pattern
of decreased emotionality in WT mice would be expected,
although Cnp1
KO-speciﬁc memory-related events cannot be
ruled out (See Fear conditioning tests). Although EPM and OF
emotionality measures were controlled for locomotor activity,
FST results could reﬂect differences in activity. Removing the
FST from the emotionality Z-score decreased power, but the
same progressive pattern of low emotionality was observed in
Cnp1
KO mice (6 months P¼0.07; 9 months Po0.0004;
Supplementary Figure 4).
Integrated Z-score measures of locomotor activity revealed
a concomitant progressive increase from 3 to 9 months of age
in Cnp1
KO mice (Figure 1d and Supplementary Figures 1–3).
Cnp1
KO mice also displayed lower body weight at 6 and 9
months compared with WT, but had normal levels of stress
hormones (Supplementary Figures 5a and b). Together,
these results are supportive of a time-dependent decrease
in emotionality in Cnp1
KO mice, which is paralleled by a
progressive elevated locomotor phenotype.
Cnp1
KO mice are resistant to developing high
emotionality states in two distinct rodent models of
depression. To test whether low baseline emotionality also
conferred reduced vulnerability to develop high emotionality
states, we exposed two independent cohorts of Cnp1
KO mice
to environmental (UCMS) or neuroendocrine (CORT) stressors
for a period of 4 weeks. In both experiments, WT groups
responded with robust and characteristic increases in
emotionality (Figures 2a and b). Cnp1
KO mice responded
with increased emotionality after UCMS compared with non-
stressed Cnp1
KO mice (Figure 2a; Supplementary Figure 6),
but displayed a trend toward lower emotionality following
CORT exposure (Figure 2b; Supplementary Figure 7).
Notably, following both paradigms, Cnp1
KO mice remained at
emotionality levels that were lower than WT non-stressed
groups (Figures 2a and b). These differences remained when
FST was excluded from Z-score analyses (Supplementary
F i g u r e s8 aa n db )a n dw e r ec o n ﬁ r m e di na ni n d e p e n d e n t
cohort (Supplementary Figure 9). Note that the UCMS Cohort
was 6 months of age at testing, hence, the low emotionality and
high locomotion of Cnp1
KO mice match prior results (Figure 1),
thus, independently conﬁrming the Baseline phenotype.
UCMS increased locomotion in WT (trend level) but not in
Cnp1
KO mice (Figure 2c; Supplementary Figure 6). CORT
exposure reduced locomotion in WT and increased locomo-
tion in Cnp1
KO mice (Figure 2d; Supplementary Figure 7).
The role of Cnp1 in mood regulation
NM Edgar et al
4
Translational PsychiatryNo notable genotype differences were seen in weight gain,
fur rating or in corticosterone levels in either paradigm
(Supplementary Figures 10a–c and 11a–c). In summary,
Cnp1
KO mice displayed reduced vulnerability to develop high
emotionality behaviors after chronic environmental and
neuroendocrine challenges, as emotionality Z-scores never
reached WT levels. Notably, dissociations between changes
in emotionality and locomotor activity were observed between
genotype groups (Figures 2e and f).
Normal fear conditioning and cellular reactivity to
stress, but reduced fear expression, suggest low
encoding of emotional salience in Cnp1
KO mice. Our
motivating study indicated reduced Cnp1 levels in the
amygdala of MDD subjects and UCMS-exposed mice. To
test whether the observed behavioral phenotype included
disrupted amygdala function, we assessed Cnp1
KO mice in
the FC paradigm (Figure 3a), a test relying on amygdala
processing. Similar to WT, Cnp1
KO mice learned to associate
the CS with the US on day 1 (Figure 3b; left panel). On day 2,
both groups showed intact extinction learning, but Cnp1
KO
mice displayed lower CS-induced freezing from the onset,
resulting in signiﬁcantly lower freezing throughout the
extinction paradigm (Figure 3b; right panel), an indication
of low fear expression.
38 No signiﬁcant differences in pain
sensitivity were observed in the hot plate test (Supple-
mentary Figure 12). These results were conﬁrmed in a
separate cohort (N¼8–12 per genotype; Po0.01 for
extinction; Supplementary Figure 13). This robust geno-
type difference was consistently observed during extinction
recall and fear renewal (day 3), and was not due to lack of
consolidation of fear memory (Supplementary Figure 14).
To assess whether the observed differences could
reﬂect baseline changes in stress-induced activation of
Figure2 EffectsoftworodentmodelsofdepressioninCnp1
KOmice.EmotionalityZ-scoresintheunpredictablechronicmildstress(UCMS)(a)andchroniccorticosterone
treatment (CORT) (b) Cohorts. Locomotion Z-scores in the UCMS (c) and CORT (d) Cohorts. Z-scores were normalized to wild-type (WT) control groups within each
experimental cohort. Differences in Cnp1
KO control groups between the cohorts reﬂect age differences (UCMS, 6 months; CORT, 3 months). Schematic diagrams of
emotionality and locomotion interactions in WT and Cnp1
KO mice across age (e) and after UCMS or CORT exposure. (f) WT mice showed dissociation in emotionality/
locomotion effects between the two depression models, whereas changes in Cnp1
KO remained along the same axis. Red asterisks represent within genotype age
comparisons. Black asterisks represent across genotype comparisons. Data represent mean±s.e.m. (N¼10–14 per group). *Po0.05, **Po0.01, ***Po0.001 and
# represent statistical trends (Po0.1).
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early gene c-Fos in the BLA of a separate cohort of
animals following a 15-min restraint stress. WT and Cnp1
KO
mice displayed similar baseline (although at trend level
for increased reactivity in Cnp1
KO mice) and similar stress-
induced number of c-Fos-positive cells (Figures 3c and d),
indicating intact BLA response to acute stress in Cnp1
KO
mice.
Upregulated oligodendrocyte- and immune-related gene
transcripts in the BLA of Cnp1
KO mice. To investigate
putative underlying amygdala-related mechanisms, large-scale
gene expression was assessed by microarray in the BLA of
WT and Cnp1
KO mice from the UCMS Cohort (Figure 4a).
Internal veriﬁcation of the array data conﬁrmed that Cnp1
levels were undetectable in Cnp1
KO mice (Figure 4b) and
downregulated in UCMS-exposed WT mice for two out of
three probes (Figure 4c).
13,22 UCMS-exposed Cnp1
KO (KO-
UCMS) mice showed a similar pattern of transcript changes
as UCMS-exposed WT mice (R¼0.72; Supplementary
Figure 15), indicating that the broad biological response to
stress is intact. However, owing to the phenotypic
differences, these UCMS-related genes are unlikely to be
related to the behavioral phenotype in Cnp1
KO mice. Instead,
on the basis of consistent low emotionality in control and
UCMS-exposed Cnp1
KO mice, we focused on genes
Figure 3 Fear conditioning (FC) and c-Fos analysis. (a) FC protocol. (b) Percent freezing during FC and extinction. (c,d) Analysis of stress-induced cFos expression in
basolateralamygdala(BLA)of wild-type(WT)andCnp1
KOmice.(c)c-Fos expressionintheamygdalaunder10 magniﬁcation, scalebar¼0.1mm. (d)Totalc-Fos-positive
cell counts. Although there was a trend (Po0.1) toward a genotype difference in the non-stressed groups, no signiﬁcant differences were found between WT and Cnp1
KO.
In all the panels, red asterisks represent within-genotype comparisons. Black asterisks represent across-genotype comparisons. Data represent mean±s.e.m.
(N¼16–19 per group and N¼9–18 per group). *Po0.05, **Po0.01, ***Po0.001.
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conditions, as potential ‘mediators’ of the behavioral
phenotype. In total, 114 ‘Cnp1
KO-associated probesets’
were identiﬁed by the following criteria: (1) signiﬁcant
difference in Cnp1
KO under control (KO-Control vs WT-
Control) and UCMS-exposed (KO-UCMS vs WT-UCMS)
conditions (Po0.01; effect size430%), (2) consistent
directionality of effect in both groups and (3) no change in
WT after UCMS (P40.1).
On the basis of prior identiﬁcation of relative glial/neuronal
enrichment of transcript origin,
39 97% of the 114 identiﬁed
transcripts were enriched in glial or mixed glial/neuronal
origin. Speciﬁcally, a systematic upregulation of oligodendro-
cyte-related transcripts was observed (24% of Cnp1
KO-
associated genes), including genes involved in structure,
function and production of the myelin sheath (Table 1).
In parallel, we observed a signiﬁcant upregulation of
immune-related transcripts (32% of Cnp1
KO-associated
genes), including genes associated with the immune comple-
ment system and major histocompatibility complex (Table 1;
see also Supplementary Table 2). Ingenuity pathway analysis
of Cnp1
KO-associated genes identiﬁed a gene network linking
oligodendrocyte with immune genes, suggesting that the
upregulation of immune-related genes may be synchronized
with the dysregulation of oligodendrocyte-related genes in
Cnp1
KO mice. Only two neuronal-enriched genes were
identiﬁed (Cortistatin and Serpina3n), suggesting minimal
structural and/or functional adjustment in neurons.
Discussion
Focusing onanoligodendrocyte gene(Cnp1)thatiscriticalfor
neuronal support and that is dysregulated in MDD, we tested
Figure 4 Basolateral amygdala (BLA) gene array analysis and real-time quantitative PCR validation (a) BLA tissue micropunch. (b) Absence of expression of the three
Cnp1 probes in Cnp1
KO mice. Expression levels were at the threshold of detection (B100–120U; gray shading). (c) Downregulation of two out of three Cnp1 probes in wild-
type (WT) mice exposed to unpredictable chronic mild stress (UCMS). (d) Real-time quantitative PCR conﬁrms signiﬁcant upregulation of eight out of nine genes. Data
representmean±s.e.m.(MicroarrayN¼11–13per group;real-timequantitativePCRN¼6pergroup).*Po0.05,**Po0.01,***Po0.001and#representstatisticaltrends
(Po0.1).
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cyte function and emotionality in mice. We show that removal
of Cnp1 in mice leads to unexpected reduced baseline
emotionality, reduced fear expression (during extinction)
and lower vulnerability to develop high emotionality states
using two rodent paradigms to induce depressive-like states.
This behavioral proﬁle suggests the presence of a dysfucn-
tional amygdala-related network that is consistent with
proposed mechanisms for stress resiliency. Gene array
analysis in the BLA of Cnp1
KO mice revealed a robust
upregulation of oligodendrocyte- and immune-related trans-
cripts, potentially representing functional compensations.
Table 1 Selection of signiﬁcantly affected neuronal, oligodendrocyte and immune-related genes between Cnp1
KO and WT control mice
Abbreviations: Alr, average log ratio (Cnp1
KO/WT); KO, knockout; WT, wild type.
Number of redundant probes is shown following the gene symbol. Red, neuronal-enriched genes; blue, oligodendrocyte-enriched genes; underline, immune-related
genes. The listed P-values represent the main genotype effect from the ANOVA analysis (see Supplementary Table 2).
  Gene Symbol Gene Title
Serpina3n serine (or cysteine) peptidase inhibitor clade A member 3N (Serpina3n)  0.81 2.13E-10
Cort (2) cortistatin 0.73 5.14E-06
Mag myelin-associated glycoprotein 1.16 6.64E-18
Tspan2 tetraspanin 2 0.95 1.51E-16
Tmem10 transmembrane protein 10 1.10 6.76E-16
Cldn11 claudin 11 0.98 2.59E-15
Adamts4 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 4 0.73 2.66E-15
Mbp myelin basic protein transcript variant 7  0.83 3.68E-15
Tmem125 transmembrane protein 125  0.80 9.05E-14
Mal myelin and lymphocyte protein T-cell differentiation protein 0.83 1.48E-13
Slc44a1 solute carrier family 44 member 1  0.73 3.90E-13
Pllp plasma membrane proteolipid  0.67 1.34E-12
Plp1 proteolipid protein (myelin) 1  0.48 2.99E-12
Gltp glycolipid transfer protein 0.56 1.80E-11
Mcam melanoma cell adhesion molecule 0.64 2.66E-11
Gjc2 gap junction protein gamma 2 (Gjc2) transcript variant 2  0.69 4.09E-11
Fgfr2 fibroblast growth factor receptor 2 transcript variant 2  0.48 5.44E-11
Cd9 CD9 antigen 0.75 9.35E-11
Rhog ras homolog gene family member G  0.63 1.62E-10
Elovl1 elongation of very long chain fatty acids-like 1 transcript variant 2  0.46 5.27E-10
Mobp (4) myelin-associated oligodendrocytic basic protein 0.95 8.59E-09
Ddr1 discoidin domain receptor family member 1 transcript variant 1  0.50 1.09E-07
Fa2h fatty acid 2-hydroxylase 0.44 5.64E-07
Pmp22 peripheral myelin protein  0.42 8.64E-07
Mog (2) myelin oligodendrocyte glycoprotein  0.77 9.17E-07
Nkx6-2 NK6 transcription factor related locus 2 (Drosophila)  0.45 1.14E-05
Lyz (2) lysozyme 1.78 8.29E-21
Ly86 lymphocyte antigen 86  0.77 3.06E-20
Cd52 CD52 antigen  1.39 4.74E-20
Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide 0.74 5.96E-18
C4a (2) complement component 4A (Rodgers blood group)  1.50 4.58E-16
Tyrobp TYRO protein tyrosine kinase binding protein  0.73 5.52E-16
Cd63 CD63 antigen 0.59 7.72E-16
Cyba cytochrome b-245 alpha polypeptide  0.65 1.49E-15
C1qa complement component 1 q subcomponent alpha polypeptide  0.70 2.67E-15
C1qb complement component 1 q subcomponent beta polypeptide  0.76 2.89E-15
Trem2 triggering receptor expressed on myeloid cells 2  0.70 8.75E-15
C4b complement component 4B (Childo blood group)  1.24 9.36E-15
C1qc complement component 1 q subcomponent C chain  0.69 3.47E-14
Fcgr3 Fc receptor IgG low affinity III  0.50 3.35E-13
Lgals3 lectin galactose binding soluble 3 0.74 5.33E-13
Ctsc cathepsin C  0.54 7.47E-13
Osmr oncostatin M receptor  0.45 2.12E-12
Hvcn1 hydrogen voltage-gated channel 1  transcript variant 1  0.41 2.77E-12
B2m (2) beta-2 microglobulin  0.56 7.65E-12
Klhl6 kelch-like 6 (Drosophila) 0.40 3.93E-10
Litaf LPS-induced TN factor  0.54 6.06E-10
Ndrg1 N-myc downstream regulated gene 1  0.56 8.96E-10
Lyz2 lysozyme 2  0.73 1.39E-09
Cd68 CD68 antigen 0.56 1.98E-09
Lag3 lymphocyte-activation gene 3  0.68 2.27E-09
Cd82 CD82 antigen  0.55 4.69E-09
Adssl1 adenylosuccinate synthetase like 1  0.48 7.37E-08
Cd74 (2) CD74 antigen (major histocompatibility complex class II antigen-associated) transcript variant 2 0.66 1.33E-06
alr      p value
(KO vs. WT)
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KO mice show a low baseline emotionality phenotype
(trait) that appears progressively over time, but that is
observed before the onset of motor coordination deﬁcits
(9–12 months), indicating that it is not due to the late-onset
widespread axonal degeneration observed in Cnp1
KO mice.
31
Rather, more discrete molecular changes in myelin structure
have been observed at earlier ages, which may contribute to
the observed phenotype. For instance, the direct functional
consequence of Cnp1 ablation is not known, but disorganiza-
tion of critical proteins (e.g., Caspr, Nav) at the paranode
region at 3 months and degeneration in some small diameter
axons as early as post-natal day 15 were reported in Cnp1
KO
mice.
30,40 Hence, impaired paranode function may trans-
late into suboptimal support for neuronal axons, hence
priming the system for dysregulated physiological responses
to stress/fear.
Cnp1
KO mice also display a concomitant increase in
locomotor activity. Tests of emotionality control for activity,
but locomotor and emotionality phenotypes are often difﬁcult
to dissociate in rodent models. In fact, quantitative trait loci
mappingstudieshaveidentiﬁedregionsonchromosomes2,7
and 8 that encode for both anxiety-related behavior and
locomotion in rats,
41 and the well-characterized high emotion-
ality and low locomotion phenotypes of mice
42 or rats
43
lacking the serotonin transporter associate with common
genetic loci.
43 Hence, instead of a confounding factor, altered
locomotor activity may represent an epistatic outcome of
genetic disruptions of emotionality regulators, which are
nevertheless dissociable under certain genetic and/or
stress-induced conditions (Figures 2e and f).
Cnp1
KO mice have normal amygdala cellular reactivity
(c-Fos measures) and fear acquisition, but display low fear
expressionduringextinctionlearning(Figure3),whichwasnot
likely due to poor consolidation of the fear memory (Supple-
mentary Figure 14). Instead, we speculate that reduced fear
expression in Cnp1
KO mice may result from low encoding of
emotionality salient stimuli (e.g., the original fear association).
Accordingly, Cnp1
KO mice respond to chronic behavioral
(UCMS) or physiological (CORT) stress (Figure 2a), but their
induced emotionality states remained signiﬁcantly below the
levels associated with depressive-like states in WT mice
(Figures 2a and b). Together, this behavioral pattern is
consistent with stress resilient phenotype. Indeed, in humans,
resilience is associated with the ability to adapt to chronic
stress
44 and to perceive stressful events in a less threatening
way,
45–47 both characteristics observed here in Cnp1
KO mice.
Fear expression is dependent on BLA function,
48,49 but is also
modulated by regions of the prefrontal cortex.
38,50 Similarly, in
humans, the ventromedial prefrontal cortex modulates amyg-
dala function during fear extinction
51, and potent ventromedial
prefrontal cortex inhibition of the amygdala is postulated to
occur in resilient individuals.
44,52 Together, this suggests the
presence of a dysfunctional amygdala-related neural network
in Cnp1
KO mice, consistent with proposed mechanisms for
stress resilience. As disruption in related networks including
prefrontal and/or hippocampal regions cannot be excluded,
future site-speciﬁc and time-dependent alterations could
further reﬁne the role of Cnp1.
Microarray evaluation of transcript levels within the BLA of
Cnp1
KO mice indicated a robust pattern of upregulated
oligodendrocyte-related transcripts. This suggests an at-
tempted compensation for the lack of structure/function due
to missing Cnp1, and potentially reﬂects prior reports of
enlargement of the myelin inner tongue in small diameter
axons and whirls of excess redundant myelin sheaths seen
early inCnp1
KO mice.
30 Microarray assessmentalso revealed
a pattern of upregulated immune-related transcripts (major
histocompatibility complex class II, complement system,
inﬂammatory mediators; Table 1), consistent with reports of
reactive gliosis and microglial activation in Cnp1
KO mice.
31
Interestingly, components of the complement system can be
either deleterious or beneﬁcial.
53 A recent report found
upregulation of certain immune-related genes (e.g., c1qc,
cd74, Serpina3, tyrobp) was associated with protected
cognition in old subjects,
54 suggesting neuroprotective
potential.Here,upregulatedimmune-relatedgenesinCnp1
KO
mice show B40% overlap with the gene set implicated in that
study,suggestingpotentialmixeddeleterious/neuroprotective
effects of immune-related gene changes in Cnp1
KO mice.
Surprisingly, only two neuronal-associated transcripts were
found changed (upregulated) in Cnp1
KO mice, and both are
associated with immune function. Cortistatin, a neuropeptide,
has anti-inﬂammatory and neuroprotective properties in
mice
55 and humans,
56,57 whereas Serpina3, a serine pepti-
dase inhibitor, is upregulated in response to inﬂammation in
the rodent brain,
58,59 suggesting a protective role for these
genes in Cnp1
KO mice.
Whether increased immune- and oligodendrocyte-related
transcriptsmaybeanattemptofthesystemto‘repair’damage
and/or protect against further damage owing to the lack of
Cnp1-related function, is not known. However, ingenuity-
based functional analyses suggest that the two processes are
inter-related, a ﬁnding consistent with reports in most mental
illnesses,
60–62 and highlighted by the comorbidity of emotion
regulation disorders (i.e., anxiety, depression) in patients with
multiple sclerosis, an inﬂammatory demyelinating central
nervous system disease.
63,64 Consequently, Cnp1 could be
a critical component of the mechanistic link between
oligodendrocytes and immune function underlying psychiatric
and other central nervous system disorders.
32,65
Although the molecular phenotype of the Cnp1
KO appears
conﬁned to non-neuronal compartments, one of the primary
functions of myelinating oligodendrocytes is to support electrical
signalconductionalongtheaxon.
66Theparanoderegion,where
Cnp1 is localized, is critical for maintaining axonal integrity.
67,68
Cnp1 and other gene products in this region are thought to
maintain optimal functioning of axonal mitochondria and it is
suggested that perturbations at the paranode could disrupt this
fragile metabolic coupling.
32 Electrophysiological changes in
oligodendrocytes can modulate axonal conduction velocity,
69
and the ﬁring of action potentials in NG2 cells is dependent on
axonal synapses,
70 highlighting the functional connectivity
between neurons and oligodendrocytes.
71 In addition, structural
changes in oligodendrocytes, speciﬁcally at the paranode
region, are suggested to be a potential mechanism for subtle
alterations in axonal conduction and associated loss of
signal integrity.
72,73 Accordingly, improper signal conduction in
amygdala-related circuitry in Cnp1
KO mice (due to paranode
disruption) could account for the low encoding of emotionally
salient information, and related phenotypic abnormalities.
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Translational PsychiatryPrevious studies reported low Cnp1 in MDD and in
response to chronic stress
13,22 (Figure 4). We now demon-
strate that disruption of oligodendrocyte function (via Cnp1
ablation) can impact circuits mediating emotionality in mice,
leading to a resilient emotionality phenotype. Thus, although
these studies indicate that Cnp1 disruption is not likely a
causal factor in MDD; the current results suggest that low
Cnp1 and/or disruption of a critical axoglial junction may
contribute to clinical symptoms of mood disorders in an
unexpected and potentially maladaptive way (due to massive
molecular changes), and should therefore be further
examined in relation to psychiatric illnesses and potential
treatments.
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